FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249297552> ?p ?o ?g. }

• W4249297552 abstract "Abstract Background Though cerebrospinal fluid (CSF) Aβ42, p‐tau181 and t‐tau have been shown to increase diagnostic accuracy for early Alzheimer’s disease (i.e. AD at the MCI stage), several challenges remain with respect to their routine clinical use. In order to address these and related issues, a multidisciplinary task force was formed (Geneva Biomarker Roadmap Initiative). Adapting a five‐phase framework for the development of cancer biomarkers (Pepe et al., 2001), this task force recently convened (2019) to provide an update on earlier publications (2017). We here provide an update for the core CSF AD biomarkers (Aβ42/Aβ40, p‐tau181 and t‐tau) and for the first time provide a review of the same measures in blood in context of the five‐phase framework. Method In a two‐day workshop (Geneva, November 2019), we convened a panel of experts in AD biomarkers. The level of maturity of CSF and blood biomarkers was assessed based on the Biomarker Roadmap (Frisoni et al., 2017). Biomarker maturity and research priorities were systemically assessed by subgroups before the meeting, and presented and discussed during the workshop. Result CSF biomarkers continued to demonstrate the highest level of maturity according to the strategic roadmap. Significant improvements compared to the 2017 summary (Mattsson et al., 2017) included the development of fully‐automated assays and the introduction of standard operating procedures for the preanalytical handling of CSF. Despite being in their infancy, the data presented and discussed for certain blood biomarkers demonstrated promising results. While t‐tau in blood did not satisfy the criteria for phase 2 (diagnostic discrimination), p‐tau181 and Aβ in blood either fully or partially fulfilled the criteria for this phase. It was agreed that only preliminary, albeit encouraging, evidence was available for the ability of blood measures to predict AD dementia in subjects with MCI (phase 3). An overview of novel CSF and blood tau biomarkers will also be discussed. Conclusion The core CSF AD biomarkers (t‐tau, p‐tau181 and Aβ) have the highest level of maturity for clinical utility. Blood biomarkers for p‐tau18, and to a lesser degree Aβ, show excellent discrimination for AD from controls and non‐AD neurodegenerative disorders." @default.
• W4249297552 created "2022-05-12" @default.
• W4249297552 creator A5001094259 @default.
• W4249297552 creator A5003042664 @default.
• W4249297552 creator A5004016764 @default.
• W4249297552 creator A5007972753 @default.
• W4249297552 creator A5013347061 @default.
• W4249297552 creator A5015109247 @default.
• W4249297552 creator A5019120747 @default.
• W4249297552 creator A5021012662 @default.
• W4249297552 creator A5023093363 @default.
• W4249297552 creator A5023438801 @default.
• W4249297552 creator A5024110469 @default.
• W4249297552 creator A5025313057 @default.
• W4249297552 creator A5027031712 @default.
• W4249297552 creator A5034480643 @default.
• W4249297552 creator A5036774533 @default.
• W4249297552 creator A5045343267 @default.
• W4249297552 creator A5046266841 @default.
• W4249297552 creator A5049919895 @default.
• W4249297552 creator A5051868596 @default.
• W4249297552 creator A5052536571 @default.
• W4249297552 creator A5053530106 @default.
• W4249297552 creator A5058052951 @default.
• W4249297552 creator A5066503440 @default.
• W4249297552 creator A5068751115 @default.
• W4249297552 creator A5079134234 @default.
• W4249297552 creator A5079766290 @default.
• W4249297552 creator A5081283156 @default.
• W4249297552 creator A5082634704 @default.
• W4249297552 creator A5089411086 @default.
• W4249297552 creator A5090920358 @default.
• W4249297552 creator A5039651438 @default.
• W4249297552 date "2020-12-01" @default.
• W4249297552 modified "2023-10-09" @default.
• W4249297552 title "Alzheimer’s disease biomarker roadmap 2020: Fluid biomarkers" @default.
• W4249297552 doi "https://doi.org/10.1002/alz.039557" @default.
• W4249297552 hasPublicationYear "2020" @default.
• W4249297552 type Work @default.
• W4249297552 citedByCount "2" @default.
• W4249297552 countsByYear W42492975522022 @default.
• W4249297552 crossrefType "journal-article" @default.
• W4249297552 hasAuthorship W4249297552A5001094259 @default.
• W4249297552 hasAuthorship W4249297552A5003042664 @default.
• W4249297552 hasAuthorship W4249297552A5004016764 @default.
• W4249297552 hasAuthorship W4249297552A5007972753 @default.
• W4249297552 hasAuthorship W4249297552A5013347061 @default.
• W4249297552 hasAuthorship W4249297552A5015109247 @default.
• W4249297552 hasAuthorship W4249297552A5019120747 @default.
• W4249297552 hasAuthorship W4249297552A5021012662 @default.
• W4249297552 hasAuthorship W4249297552A5023093363 @default.
• W4249297552 hasAuthorship W4249297552A5023438801 @default.
• W4249297552 hasAuthorship W4249297552A5024110469 @default.
• W4249297552 hasAuthorship W4249297552A5025313057 @default.
• W4249297552 hasAuthorship W4249297552A5027031712 @default.
• W4249297552 hasAuthorship W4249297552A5034480643 @default.
• W4249297552 hasAuthorship W4249297552A5036774533 @default.
• W4249297552 hasAuthorship W4249297552A5039651438 @default.
• W4249297552 hasAuthorship W4249297552A5045343267 @default.
• W4249297552 hasAuthorship W4249297552A5046266841 @default.
• W4249297552 hasAuthorship W4249297552A5049919895 @default.
• W4249297552 hasAuthorship W4249297552A5051868596 @default.
• W4249297552 hasAuthorship W4249297552A5052536571 @default.
• W4249297552 hasAuthorship W4249297552A5053530106 @default.
• W4249297552 hasAuthorship W4249297552A5058052951 @default.
• W4249297552 hasAuthorship W4249297552A5066503440 @default.
• W4249297552 hasAuthorship W4249297552A5068751115 @default.
• W4249297552 hasAuthorship W4249297552A5079134234 @default.
• W4249297552 hasAuthorship W4249297552A5079766290 @default.
• W4249297552 hasAuthorship W4249297552A5081283156 @default.
• W4249297552 hasAuthorship W4249297552A5082634704 @default.
• W4249297552 hasAuthorship W4249297552A5089411086 @default.
• W4249297552 hasAuthorship W4249297552A5090920358 @default.
• W4249297552 hasBestOaLocation W42492975521 @default.
• W4249297552 hasConcept C101433766 @default.
• W4249297552 hasConcept C104317684 @default.
• W4249297552 hasConcept C124535831 @default.
• W4249297552 hasConcept C126322002 @default.
• W4249297552 hasConcept C138496976 @default.
• W4249297552 hasConcept C143998085 @default.
• W4249297552 hasConcept C151730666 @default.
• W4249297552 hasConcept C15744967 @default.
• W4249297552 hasConcept C17744445 @default.
• W4249297552 hasConcept C199539241 @default.
• W4249297552 hasConcept C22467394 @default.
• W4249297552 hasConcept C2779134260 @default.
• W4249297552 hasConcept C2779343474 @default.
• W4249297552 hasConcept C2781197716 @default.
• W4249297552 hasConcept C46111723 @default.
• W4249297552 hasConcept C55493867 @default.
• W4249297552 hasConcept C71924100 @default.
• W4249297552 hasConcept C86803240 @default.
• W4249297552 hasConceptScore W4249297552C101433766 @default.
• W4249297552 hasConceptScore W4249297552C104317684 @default.
• W4249297552 hasConceptScore W4249297552C124535831 @default.
• W4249297552 hasConceptScore W4249297552C126322002 @default.
• W4249297552 hasConceptScore W4249297552C138496976 @default.
• W4249297552 hasConceptScore W4249297552C143998085 @default.
• W4249297552 hasConceptScore W4249297552C151730666 @default.
• W4249297552 hasConceptScore W4249297552C15744967 @default.

• next